Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well all you SFIO Bag holders. The company doesn't seem to want to help us out. So I think it's time that we start to spread the word ourselves. If your up for it start picking groups & spread it before the magical report comes out we have 4 days left if they actually produce it
A REAL PR. Better grab the cheapies
https://finance.yahoo.com/news/starfleet-innotech-reports-second-quarter-132500450.html
SFIO meeting today video
2 new posts SFIO 2nd Qt coming by or on the 15th and Project fort is selected
2nd Quarter Financials & Disclosure will be posted on or before 15 AUG. What to expect?
— SFIO - Starfleet Innotech, Inc. (@StarfleetInno) August 11, 2022
✅Stable & strong financials
✅New opportunities (i.e. M&A, project status, new engagements)
✅Shares restructure (OS reduction)
✅Strategic Outlook & expansion plan of the company$SFIO
Starfleet portfolio company PROJECT FORT was selected among eight startups to join Makati City Mayor Abby Binay's bid to transform Metro Manila's CBD into the Silicon Valley of the Philippines. BIG partnerships brewing! Stay tuned! $SFIO https://t.co/qyauj46czs
— SFIO - Starfleet Innotech, Inc. (@StarfleetInno) August 11, 2022
Seen this
New to this board thought I would just check in.
3 new tweets from HIRU today I'm sure you have seen them if not here you go.
https://twitter.com/Hirucorpnew
They tried to knock it down But buyers prevail again. Who was saying this morning that it was done with and headed down ct aka Pastor K. But look again GREEN that's what 7 in a row.
STAY GREEN
Here is a email I received back from SFIO on 8/1 when i asked Jeths about Sevenbank
SFIO Admin
Aug 1, 2022, 7:09 PM (8 days ago)
to me
Hi Greg,
We have no connection with Servenbank and / or Hatadi Supaat including any of their partners.
Hatadi Supaat is a shareholder of the company due to his facilitation of the purchase of SFIO ticker (merger). We are not involve with his dealings nor the dealings of Servebank. He is not also an officer of SFIO.
Regards,
--
Jeths Lacson, CPEng
Nice we closed above .025 up 30.26% for the day. Good momentum now and the chart has definitely made a nice upward bottom turn. This should definitely turn some heads and increase the volume tomorrow.
Stay GREEN
Here is the latest episode of meet the fleet. If anyone hasn't seen it.
Epiphany Café looks pretty busy
You're going to have to wait awhile you missed the boat on episode 6
Another green day for SFIO what's that 5 in a row. Chart looks great looking like we will clear above .02 tomorrow. Starting to see some new blood buying now. Also I like seeing more upbeat posts.
Have a great night and a GREEN day tomorrow
Starfleet Innotech Announces Completion of Reg-A Offering, Reduction in Outstanding Shares??
?Reduction of OS by converting officers/key partners shares into the new Preferred Shares
?Completion of the initial Reg-A by a long-term strategic investor
Starfleet Innotech Announces Completion of Reg-A Offering, Reduction in Outstanding Shares🌐
— SFIO - Starfleet Innotech, Inc. (@StarfleetInno) August 5, 2022
✅Reduction of OS by converting officers/key partners shares into the new Preferred Shares
✅Completion of the initial Reg-A by a long-term strategic investor$SFIO @SFIO_Inc pic.twitter.com/mTJoevBp3J
Very nice week for SFIO lots of GREEN days at the close and the toper closed at the daily high on a Friday. Can't wait for next week. The chart finally looks to have a nice upward bottom turn. You all have a great weekend.
MH
Really
Latest contact from Hiru Corp
Conversation
@Hirucorp
@Hirucorpnew
Working on canceling another 73 Million shares to bring the restricted to 8 Million and O/S under 1.4 Billion, More news coming.
Kathryn
Sit and watch I got out of OREX at 6.28 on Friday. I feel that 5.30 was the bottom I had the main support at 5.26. But did not have the balls to get back in being it was Friday. So my plan is to watch all of the weight loss stocks (I have found 8 of them) and jump in to one or two of them on Monday.
I am jus waiting for ARNA to settle down for now OREX is blowing it away
Good morning all new here. I bailed out of ARNA on wendsday at the spike and moved over here yesterday am and bought in at 5.32 I think I will camp out here for awile its looking good.
New Short Sale Rule
Prior to July 6 there was a rule that limited when a short sale of stock could be executed, otherwise known as the Uptick Rule (Rule 10a-1 under the Securities Exchange Act of 1934). This past July, the SEC eliminated the Uptick Rule. Because you can now short a stock with less limitation, many people are wondering if this has caused an increase in volatility in the stock market.
There have been many articles and blogs written about this very subject. Since the rule elimination, the U.S. markets have experienced the highest volatility levels since 2003?, and the NYSE has experienced its highest historical volume. Some believe that there is more than just a coincidence between the elimination of the Uptick Rule and the recent market swings. It is important to note many other changes in the markets have occurred recently (such as the increased automation of some markets and Reg. NMS), so it is difficult to quantify exactly how much impact the elimination of the Uptick Rule had on the markets. However, there are still some interesting points to consider.
First, the NYSE Tick Index ($USN/TICK) indicates the number of stocks on the NYSE that are trading on an uptick, minus those that are trading on a downtick. Since the elimination of the Uptick Rule, this index has been much lower than normal despite strong positive days in the markets. Some theorize that hedge funds and large institutions, previous to the rule elimination, created upticks in order to execute short sales.
The second fact to consider is that the short interest has been increasing and that this is the most heavily shorted market in history?. The ability to short was being well practiced before the Uptick Rule was eliminated. Considering that the short interest on the NYSE reached all time highs in each of the four months prior to the Uptick Rule elimination, and since then, the short interest has decreased every month. Remember the more outstanding short shares, the greater the likelihood of violent swings to the upside in short-covering rallies.
Finally, a study by Ohio State University professors conducted after a pilot test of the elimination of the Uptick Rule showed the Uptick Rule elimination did not result in an increase in daily volatility. However, the pilot program was before other changes in the market - such as the increased automation of the markets and Reg NMS. Also, the study did not take into account the possibility of using short selling to manipulate small cap, micro cap and other thinly traded issues.
So, in conclusion, did the elimination of the Uptick Rule affect volatility? I think it did. But I believe the volatility in the structured credit market initiated by the subprime collapse is the real culprit. Remember that short-sellers are still required to go through the cumbersome process of borrowing shares before they short. This is not a blank check to short shares whenever anyone pleases.
Brian Bachelier
Market Structure Analyst at Scottrade
?"highest volatility since 2003"
?"most heavily shorted market in history"
Arena Pharmaceuticals and Eisai Announce FDA Approval of BELVIQ(R) (lorcaserin HCl) for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
-- First Prescription Weight-Loss Treatment Approved by FDA in 13 Years --
-- Eisai to Launch BELVIQ in U.S. Following DEA's Completion of Scheduling Review --
SAN DIEGO and WOODCLIFF LAKE, N.J., June 27, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes). The indication includes the following limitations of use: The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss and the effect of BELVIQ on cardiovascular morbidity and mortality have not been established.
"The FDA approval of BELVIQ is an important development for patients who struggle with obesity or are overweight with comorbidities and need help with chronic weight management beyond diet and exercise," said Jack Lief, Arena's President and Chief Executive Officer. "We thank our entire team and the patients who participated in our clinical trial program for making this achievement possible."
Three double-blind, randomized, placebo-controlled trials demonstrated that BELVIQ along with diet and exercise was more effective than diet and exercise alone at helping patients lose 5% or more of their body weight after one year and managing the weight loss for up to two years.
"Diet, exercise and behavioral therapy alone may not result in sustained weight loss for many overweight and obese people trying to lose weight," said Lonnel Coats, President and Chief Executive Officer, Eisai Inc. "BELVIQ represents an important therapeutic option for physicians responsible for the medical management of their patients who are overweight or obese."
In clinical trials, the most common adverse reactions for patients without diabetes treated with BELVIQ were headache, dizziness, fatigue, nausea, dry mouth, and constipation. In patients with diabetes, the most common adverse reactions were hypoglycemia, headache, back pain, cough, and fatigue.
The FDA has recommended that BELVIQ be classified by the U.S. Drug Enforcement Administration (DEA) as a scheduled drug. The DEA will review the FDA's recommendation and determine the final scheduling designation. Once the DEA has provided the final scheduling designation, Eisai will announce when BELVIQ will be available to patients and physicians in the United States.
Arena will manufacture and supply the finished commercial product from its facility in Switzerland, and Eisai will market and distribute BELVIQ in the United States.
As part of the approval of BELVIQ, the companies committed to conduct post-marketing studies to assess the safety and efficacy of BELVIQ for weight management in obese pediatric patients, as well as to evaluate the effect of long-term treatment with BELVIQ on the incidence of major adverse cardiovascular events in overweight and obese subjects with cardiovascular disease or multiple cardiovascular risk factors. The cardiovascular outcomes trial will include echocardiographic assessments.
Conference Call & Webcast
Arena will host a conference call and webcast today, June 27, 2012, at 2 p.m. Eastern Time (11 a.m. Pacific Time) to provide a business update. The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "BELVIQ" conference call. The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About BELVIQ (lorcaserin HCl)
BELVIQ (lorcaserin hydrochloride) is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain.
For more information about BELVIQ, click here for the full prescribing information or go to http://us.eisai.com/package_inserts/BelviqPI.pdf
BELVIQ Phase 3 Clinical Trial Program
The BELVIQ Phase 3 clinical trial program consisted of three double-blind, randomized, placebo-controlled trials: BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus). All three trials included a standardized program of diet, moderate exercise and behavioral counseling for both the placebo and BELVIQ groups.
BLOOM evaluated BELVIQ versus placebo over a two-year treatment period in 3,182 non-diabetic, obese (BMI of 30 to 45 kg/m2) adult patients (18 to 65 years old) with or without comorbid conditions and non-diabetic, overweight (BMI of 27 to 29.9 kg/m2) adult patients with at least one weight related comorbid condition.
BLOSSOM evaluated BELVIQ versus placebo over a one-year treatment period in 4,008 non-diabetic, obese (BMI of 30 to 45 kg/m2) adult patients (18 to 65 years old) with or without comorbid conditions and non-diabetic, overweight (BMI of 27 to 29.9 kg/m2) adult patients with at least one weight related comorbid condition.
BLOOM-DM evaluated BELVIQ versus placebo over a one-year treatment period in 604 obese (BMI of 30 to 45 kg/m2) and overweight (BMI of 27 to 29.9 kg/m2) adult patients (18 to 65 years old) with type 2 diabetes who were receiving oral antihyperglycemic agents.
Indications
BELVIQ is indicated to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
• 30 kg/m2 or greater (obese), or
• 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)
Limitations of Use:
• The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations have not been established
• The effect of BELVIQ on cardiovascular morbidity and mortality has not been established
Important Safety Information
• Pregnancy: BELVIQ should not be taken during pregnancy or by women who are planning to become pregnant.
• Nursing: BELVIQ should not be taken while breastfeeding.
• Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions: BELVIQ and certain medicines for depression, migraine, the common cold, and mood, anxiety, psychotic or thought disorders or other medical problems may affect each other causing serious or life-threatening side effects. Patients should tell their doctor if they are taking medicines to treat any of these conditions such as: triptans, tricyclics, lithium, selective serotonin uptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or antipsychotics; linezolid, an antibiotic; tramadol; dextromethorphan, an over-the-counter medicine used to treat the common cold or cough; over-the-counter supplements such as tryptophan or St. John's Wort. BELVIQ and these medicines should be discontinued immediately and symptomatic treatment measures should be initiated if patients taking BELVIQ and these other medicines experience any of the following: mental changes such as agitation, hallucinations, confusion, or other changes in mental status; coordination problems, uncontrolled muscle spasms, or muscle twitching (overactive reflexes); restlessness; racing or fast heartbeat, high or low blood pressure; sweating or fever; nausea, vomiting, or diarrhea; or muscle rigidity (stiff muscles).
• Valvular Heart Disease: Certain weight loss drugs have been associated with problems with the valves in the heart. Patients taking BELVIQ who have trouble breathing, swelling of the arms, legs, ankles, or feet, dizziness, fatigue, or weakness that will not go away, or fast or irregular heartbeat should call their doctor right away. Before taking BELVIQ, patients should tell their doctor if they have or had heart problems including congestive heart failure, or heart valve problems. Patients should not take BELVIQ in combination with drugs that have been associated with valvular heart disease (such as cabergoline). Patients who develop signs and symptoms of valvular heart disease while taking BELVIQ should be evaluated and discontinuation of BELVIQ should be considered by their doctor.
• Changes in Attention or Memory: Problems with thinking, sleepiness, confusion, and fatigue have been reported in patients taking BELVIQ.
• Patients taking BELVIQ should not drive a car or operate heavy machinery until they know how BELVIQ affects them.
• Mental Problems: Taking BELVIQ at higher than the recommended dose may cause psychiatric problems such as: hallucinations, feeling high or in a very good mood (euphoria), feelings of standing next to yourself or out of your body (disassociation). The recommended dose of 10 mg twice daily should not be exceeded. Patients should be monitored for the development or worsening of depression, suicidal thoughts or behaviors, and/or any changes in mood. BELVIQ should be discontinued if patients develop suicidal thoughts or behaviors.
• Low Blood Sugar (Hypoglycemia): Weight loss can cause low blood sugar in people with type 2 diabetes mellitus who are on medicines to treat it such as metformin, insulin, or sulfonylureas. Blood sugar levels should be monitored for patients who take BELVIQ. Changes to medicines may be needed if low blood sugar develops.
• Painful Erections (Priapism): If patients taking BELVIQ experience an erection lasting more than 4 hours, whether it is painful or not, they should stop using BELVIQ and call their doctor or go to the nearest emergency room right away. BELVIQ should be taken with caution by men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with a deformed penis. Patients should tell their doctor if they take medicines used to treat erectile dysfunction.
• Slow Heartbeat: BELVIQ may cause a slow heartbeat. Patients taking BELVIQ should tell their doctor if they have a history of a slow heartbeat or heart block.
• Decreases in Blood Cell Count: BELVIQ may cause decreases in red or white blood cell count. A doctor may do tests to check a patient's blood cell count during treatment with BELVIQ.
• Increase in Prolactin: BELVIQ may increase the amount of a hormone the body makes, called prolactin. Patients taking BELVIQ should tell their doctor if their breasts begin to make milk or have a milky discharge or if their breasts begin to increase in size.
• Increased Pressure in the Arteries of the Lung (Pulmonary Hypertension): Certain weight loss drugs have been associated with the rare but life-threatening side effect of increased pressure in the arteries of the lung. It is unknown if BELVIQ increases the risk for this condition.
• Most Common Adverse Reactions In Non-Diabetic Patients: Headache, dizziness, fatigue, nausea, dry mouth, and constipation.
• Most Common Adverse Reactions in Diabetic Patients: Hypoglycemia, headache, back pain, cough, and fatigue.
• Response to BELVIQ should be evaluated at 12 weeks of treatment to determine if therapy should be discontinued.
For more information about BELVIQ, click here for the full prescribing information or go to http://us.eisai.com/package_inserts/BelviqPI.pdf
About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc., is a biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. For more information about Arena Pharmaceuticals, please visit www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.
BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.
About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the importance of the FDA approval of BELVIQ; the safety, efficacy, mechanism of action, DEA scheduling and commercialization of BELVIQ; the use of BELVIQ by patients and physicians; rights and obligations under the marketing and supply agreement with Eisai; future studies of BELVIQ; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing and outcome of DEA, EMA and other regulatory review is uncertain; limitations on the indicated uses, restricted distribution methods and other limitations on BELVIQ or, if approved, any of our other drug candidates; risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from BELVIQ, including timing and impact of competition; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than we or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of our research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review, approval or continued marketing; our ability to obtain and defend our patents; the timing, success and cost of our research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Contacts: Arena Pharmaceuticals, Inc. Contacts: Eisai Inc.
858.453.7200
Investor Inquiries: Russo Partners Investor Inquiries:
Cindy McGee Alex Scott
cindy.mcgee@russopartnersllc.com
alex_scott@eisai.com
619.213.6995 201.746.2177
Media Inquiries: Russo Partners Media Inquiries:
David Schull Marcia Diljak
david.schull@russopartnersllc.com
marcia_diljak@eisai.com
858.717.2310 201.746.2236
www.arenapharm.com
www.eisai.com/us
SOURCE Arena Pharmaceuticals, Inc.
You are subscribed to Arena Pharmaceuticals, Inc. Investor Relations' e-mail alerts as petersfmly@gmail.com.
To update your e-mail and alert preferences, please click here.
To unsubscribe, please click here.
Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive , San Diego, CA 92121
Service provided by Shareholder.com
Top Gainers in Pre-market Today, Jun-26
6/26/2012 8:02:55 AM
These are the stocks gaining the most in pre-market trading on, Tuesday, June 26, 2012.
Be sure to check out our Pre Market section of TheStockMarketWatch.
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) is currently trading at $9.58 up 4.2% in pre-market on 20570 shares traded. ARNA is trading 72.41% above its 50 day moving average and 245.32% above its 200 day moving average. ARNA is -23.27% below its 52-week high and 647.97% above its 52-week low.
Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering medical advances and new options for patients.
Read more: http://fyxnews.com/smw/29760/Top-Gainers-in-Pre-market-Today-Jun-26#ixzz1yu9Y8ghH
0001 in a week this realy sucks
I am down 5k now
and there is nothing we can do about it
Well all I can say is that we are Fucced
It is like buying a loto ticket and checking it in a year or planting a pot plant by a river and coming back in six months you guys are going to drive your selves crazy just do not look at it for at least 2 months
Ok that was good best laugh of the day
Same Here
I also opend a account at Etrade on Saturday and wired funds into it that way I should be good to go on Tuesday. This was my last straw for ST I am done with them.
Yep I get the same thing
* If the price is under $1 at the time of execution, commission is $7 + 1/2% of the principal
Buy/Sell: SELL Calculator
Unable to accept the order because your account does not have enough shares available for sale. You may already have open sell orders in this security, or may not own enough shares in this security to complete this transaction. Please review your open orders and position to determine the amount available for sale. If you have further questions, please contact your local branch office.
Shares:784,000 AON
Please contact your local branch about placing an order on this security.
Symbol: Find Symbol
Order Type:
Unable to enter the order because the limit price entered is too far away from the market price for stocks under $10.
Limit Price: $.85
Duration:
SFIO : Pink Sheets
Smokefree Innotec In...
Last: 0.02
Change: 0.00 0%
Bid/Size: 0.0195/246243
Ask/Size: 0.02/200000
Volume: 182,287,428
52 week high: 0.55
52 week low: 0.00
as of 10:07 AM ET 7/4/2011
Yea I called etrade today and they said no lock down ST is the only one who is locked down and guess were my shares are ST so I opend a acount with ET today and will transfer them on tuesday
PENNY LAND HERE WE COME
NEWS Rapid Fire Marketing's Bionic Cigs Website Fully Operational - Electronic Cigarette Market Growing
6 minutes ago - PR Newswire via Comtex
PR Newswire
Rapid Fire Marketing (OTC Pink: RFMK) announced today that their wholly owned subsidiary's website BionicCigs.com, a seller of electronic cigarettes is now fully operational. Sales of Bionic Cigs products are now completed entirely within the site with no third party sites involved to complete the purchasing process. The company considers this a big step in the branding of the Company because the entire process is conducted within the Bionic Cigs site with no need to send buyers to a third party checkout platform.
Additionally, the Company has implemented a top notch Public Relations and Search Marketing Firm to market the Company and its products all across the Internet on a global scale. It is the Company's goal to be ranked on page one for Google searches relating to electronic cigarettes. The Company has already seen a dramatic increase in traffic and Alexa ratings to the site.
Bionic Cigs is offering 50 percent off all products for the month of July to show appreciation for current and new customers for their patience with the website process. Electronic cigarettes such as Bionic Cig's continue to gain popularity all across the globe. Nearly 46 million Americans smoke cigarettes. About 40 percent try to quit each year, according to the Centers for Disease Control and Prevention. Electronic cigarettes have grown from a few thousand users in 2006, when they were first introduced to several million users in 2011. A number of makers and distributors of electronic cigarettes state that tens of thousands of new users are switching to the safer alternative.
Users say that electronic cigarettes address not only the nicotine addiction, but the behavioral aspects of smoking. With an electronic cigarette, the holding of the 'cigarette', the puffing, and seeing the smoke come out is a much more satisfying experience than patches and pills. There are far fewer risks and chemicals involved with electronic cigarettes when compared to the more than 4,000 chemicals found in standard cigarettes.
"We are very pleased that the challenging process of building an ecommerce website for the purposes of selling our products is finally complete. But, we overcame all of the obstacles and we have now moved into a much more productive aspect of the business, which is the marketing and sales of our products," said Mike Amezquita, President. "We will be announcing details of our comprehensive marketing program as it unfolds, such as the sponsorship announced with the Brickyard 400 NASCAR race July 29th through July 31st. Further we expect to announce our sales figures every 3 months as the Company grows."
Safe Harbor:
From time to time, the Company may issue news releases that contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statement provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward-looking statements." "Forward-looking statements" are based upon expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those anticipated.
SOURCE Rapid Fire Marketing
Agreed
I do not really care they are mine now and I am holding long and strong
That was cool I got filled at .0371 and .0373 what is wrong with that
Yes I am picked up another 300k at .0052